Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide
Sabine Käyser(German Cancer Research Center), Uwe Platzbecker(National Center for Tumor Diseases), B. Douglas Smith(Johns Hopkins University), Roland B. Walter(Rafael Advanced Defense Systems (Israel)), Alan K. Burnett(Cardiff University), Gerhard Ehninger(University Hospital Carl Gustav Carus), Christoph Röllig(University Hospital Carl Gustav Carus), Axel Benner(Memorial Sloan Kettering Cancer Center), Nigel H. Russell(Guy's and St Thomas' NHS Foundation Trust), Zdeněk Ráčil(Masaryk University), Robert K. Hills(Cancer Research UK Clinical Trials Unit), Maria R. Baer(University of Maryland, Baltimore), Kelly J. Norsworthy(United States Food and Drug Administration), Richard F. Schlenk(German Cancer Research Center), Jiřı́ Mayer(Masaryk University), Elihu H. Estey(University of Washington), Tomáš Szotkowski(University Hospital Olomouc), Michelle A. Elliott(Mayo Clinic), Jan Novák(Institute of Haematology and Blood Transfusion), Anthony D. Ho(Heidelberg University), Patrick Gonzales(Memorial Sloan Kettering Cancer Center), Julia Krzykalla(German Cancer Research Center), Mark J. Levis(Sidney Kimmel Cancer Center), Martin Görner(Klinikum Bielefeld), П. П. Зак(Charles University), David Grimwade(King's College School), Jörg Westermann(Palmetto Hematology Oncology), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), A. Krämer(German Cancer Research Center), Christian Thiede(University Hospital Carl Gustav Carus)
Cited by 42
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k